Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoproliferative Disorders

Smoldering Multiple Myeloma

Waldenstrom Macroglobulinemia

Leukemia

Leukemia, Lymphoid

Neoplasms by Histologic Type

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Precancerous Conditions

Hypergammaglobulinemia

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Irene Ghobrial, MD

The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS and IgG or IgA LPL. These samples will become part of a tissue bank and will be used in ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify what factors result in normal cells becoming cancer; to determine how to improve treatment options; to study how the immune system identifies abnormal cells; and to evaluate the immune function in these diseases. The investigators will also study the tumor cells at the level of the participant's genes to develop treatment strategies as well as to better understand how biologic differences affect patient outcomes.

* Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced.
* Participants will then receive instructions for the tissue banking procedure, which involves donating bone marrow and blood samples. These will be collected only at times when necessary clinical bone marrow samples are obtained and will not require an extra visit to the doctor.
* The investigators are also requesting permission to collect medical information from the participant's record and link this information to the specimens so that we may better understand the participant's response to treatment. For samples obtained prior to beginning therapy, this information might allow us to develop new ways of predicting response to therapy. The investigators are also requesting permission to store samples of blood and bone marrow to establish a tissue bank for future research to these diseases. These samples will be de-identified; any of the participant's personal health information identifiers will be removed.
* The tumor sample may be obtained at diagnosis, during treatment and/or as the time of relapse. The timing of sample collection will coincide with other bone marrow tests required to assess the response to therapy or any other clinical purpose.

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Medical Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

To establish a databank of patients with MM, WM, MGUS, sMM, or related disorders. This databank will include medical history data and bone marrow and peripheral blood samples.

To determine whether patients with MM, WM, MGUS, sMM, or related disorders have unique proteomic, genetic and epigenetic characteristics in the malignant clone or the microenvironment and linking information to the clinical characteristics of the patients through exploratory tests.

Dana-Farber Cancer Institute

Principal Investigator

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Amino Acids

Acalabrutinib

Bendamustine Hydrochloride

Rituximab

Antineoplastic Agents, Immunological

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

100 mg Acalabrutinib (ACP-196) oral capsules twice daily for 1 year

Bendamustine and rituximab will be given for 6 x 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).

100 mg oral capsules twice daily for 1 year

Bendamustine

day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).

Neil L Berinstein, MD

Neil Berinstein

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)). Concomitantly, participants will receive 100 mg of the investigational product, Acalabrutinib, orally for 1 year (365 days) at 100 mg BID.

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with WM. Patients will require a biopsy to confirm the pathology and molecular testing for MYD88, CXCR4 and P53 mutations. A bone marrow aspiration and biopsy will be performed to document WM and MRD. Participants will be classified into clinical risk categories based on the International Prognostic Scoring (IPS) System for WM. Symptomatic, previously untreated patients will receive SOC bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)).

Concomitantly, participants will receive 100 mg of the investigational product, Acalabrutinib, orally for 1 year (365 days) at 100 mg BID. Patients will have pre-treatment computed tomography (CT) scans, and CT scans at 7, 12 and 18 months. Best objective response will be documented using the criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia. Assessment of metabolic uptake by positron emission tomography (PET) scan is not considered appropriate for WM as WM usually do not take up fluorodeoxyglucose (FDG). Patients with WM will also have disease assessed using measurements of serum IgM, serum protein electrophoresis (SPE), immunofixation (IFA), and viscosity assessments measured serially. A bone marrow aspiration and biopsy will be done before treatment and at response assessment at cycle 6 and will be repeated if positive. Durability of response will also be assessed at 18 months.

Participants will be followed by extended follow-up by telephone for up to 6 years to obtain data on the secondary endpoints.

Bendamustine, Rituximab and Acalabrutinib

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's Macroglobulinemia

To document the best combined CR and VGPR rate of first-line treatment with bendamustine and rituximab plus acalabrutinib in patients with WM using response criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia9. Response will be documented at cycle 7, 12 and 18 (durable CR).

using criteria from 6th international workshop on WM

MRD will be assessed at three on treatment timepoints (before start of cycles 7, 12, 18) as well as extended follow-up vistis. MRD will be measured from two body compartments-peripheral blood and bone marrow. MRD will be recorded and will be reported based on the limit of detection of the assay (to be determined). Results will be pooled and rates of MRD negativity for the assay will be recorded at each time point for the pooled patients and for each of the two body compartments that are being assessed.

OS will be determined using the time from first day of study treatment to death for each patients. Results for each patient will be pooled to derive an overall survival rate.

PFS will be defined as the time from first dose of study treatment to the first objective documentation of progressive disease (PD), the start of an alternative anticancer therapy, or death from any cause during study. Results for each patient will be pooled to derive an overall progressive free survival rate. Participants not meeting criteria for PD will be followed by telephone every 6 months for up to six years from the time of first dose.

A descriptive analysis of safety will be performed with descriptions of frequency and grade of the adverse events including adverse events of special interest such as hypertension, cardiac arrhythmias and bleeding events. The common toxicities described in the NCK common terminology criteriae for adverse events (NC CTAE v5.0) will be documented and grade in each patient at each visit throughout the trial. Rates and severity of all of these toxicity will be collected and reported.

Defined as the length of time a participant is identified as CR or VGPR until they progress. Different from PFS

Defined as the amount of time from the start of trial until the patient requires a new form of treatment to treat their WM

AstraZeneca

Sunnybrook Health Sciences Centre

Panobinostat

Histone Deacetylase Inhibitors

30 mg three days a week (Mondays, Wednesdays and Fridays).

1 cycle was 28 days

Dose modifications for attributable toxicities allowed for reduction to:

* 25 mg, 20 mg three times a week every week
* Or 20 mg three times a week every other week. No dose re-escalation was allowed.

  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.

LBH589

The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the same activity in people with Waldenstrom's Macroglobulinemia. This drug has been used in research for the treatment of other types of cancer, such as multiple myeloma.

This phase II study is designed to assess the toxicity profile and the proportion of overall response in patients with relapsed or refractory WM. This will study the effect of single agent LBH589 on response in these patients. Efficacy measures will include both objective clinical measurements and investigator-reported outcomes. Response and time to event analyses will follow the criteria set forth in the International Waldenstrom consortium recommendations. Prior to the start of the study, investigators will assess disease and perform a CT scan of the chest, abdomen and pelvis.

Response will be assessed after 2 cycles. If patients have stable disease or response, then they will continue on therapy until progression or unacceptable toxicity, being assessed every cycle until the sixth cycle and then every 3 months. Patients who show progression after 2 cycles will come off therapy and undergo event monitoring every 3 months. All responses will be assessed by M-protein quantification and immunofixation from serum and IgM monoclonal protein level. In addition, BM biopsies will be done at baseline, at the end of cycle 6 and at the end of all therapy. The protocol was amended because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Overall response rate is percentage of participants with complete (CR), very good partial (VGPR), partial (PR), or minimal response (MR) as best response during treatment.

CR

* Disappearance of monoclonal protein by immunofixation
* No histologic evidence of bone marrow involvement
* Resolution of any adenopathy/organomegaly (confirmed by CT scan), or signs or symptoms attributable to WM.
* Second immunofixation required for confirmation.

VGPR

-At least 90% reduction of serum monoclonal IgM concentration on protein electrophoresis.

PR

* At least 50% reduction of serum monoclonal IgM concentration on protein electrophoresis and at least 50% decrease in adenopathy/organomegaly on physical examination or on CT scan.
* No new symptoms or signs of active disease.

MR

* At least 25% but less than 50% reduction of serum monoclonal IgM by protein electrophoresis.
* No new symptoms or signs of active disease.

Progression free survival (PFS) is defined as the time from start of treatment to disease progression or death from any cause as estimated by Kaplan Meier methods. Patients who have not progressed and are alive are censored at the date the patient is known to be progression-free.

Time to progression (TTP) is defined as the time from start of treatment to progression. Patients who have not progressed are censored at the date the patient is last known to be progression free.

Duration of response DR is defined as the time from the date of first response after treatment to the date of disease progression Patients who have died for any cause or are alive without progression are censored at the date the patient is last know to be progression-free.

Duration of response DR is defined as the time from the date of first response after treatment to the date of disease progression or death for any cause. Patients who are alive without progression are censored at the date the patient is last know to be progression-free.

Grade 3 thrombocytopenia is defined as having 25,000-50,000 /uL platelets

Grade 4 thrombocytopenia is defined as having \< 25,000 /uL platelets

Acetylated-histone-H3 levels were obtained through bone marrow biopsies and measured using established methods. This analysis aimed to analyze the association between overall response and percent change of acetylated histone h3 in samples using a paired t-test.

Brigham and Women's Hospital

Novartis

Serious AEs (SAE) were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher. All remaining AEs are classified as Other AEs (OAE) including grade 3 or higher events with treatment-attribution of unlikely and unrelated plus all grade 1 and 2 events. Maximum grade toxicity by type was then calculated within SAE and OAE datasets. No further data is available to specify classification of other beyond the general term.

30 mg three days a week (Mondays, Wednesdays and Fridays).

1 cycle was 28 days

Dose modifications for attributable toxicities allowed for reduction to:

* 25 mg, 20 mg three times a week every week
* Or 20 mg three times a week every other week. No dose re-escalation was allowed.

  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.

LBH589

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

Median IgM

Median M Spike

Median Platelets

Median Hemoglobin

Median Beta 2 Microglobulin

Percentage of Bone Marrow Involvement

Lymph Nodes and Hepatocyte Selection Medium Assessment by CT Scan Evidence of Disease

Measure Description: Low is defined as 1 or dewer of the following:

Hemoglobin (HB) \<=11.5 g/dL Platelet (PT) \<=100 x 10\^9 / L Beta 2 Microglubin (B2M) \> 3 mg/L Immunoglobulin M (IgM) \> 7 g/dL

Intermediate is defined as over 65 years old or two of the following:

HB \<=11.5 g/dL PT \<=100 x 10\^9 / L B2M \> 3 mg/L IgM\> 7 g/dL

High is defined as more than 2 of the following:

Over 65 years old HB \<=11.5 g/dL PT \<=100 x 10\^9 / L B2M \> 3 mg/L IgM\> 7 g/dL

International Prognostic Scoring System for Waldenstrom Macroglobulinemia

Irene Ghobrial

Overall Response Rate

Median Progression Free Survival

Median Time to Progression

Median Duration of Response

Number of Participants With Grade 3 and 4 Treatment-Related Thrombocytopenia

Only three complete sample (baseline and post-therapy) were ascertained. The difference in percentage of acetylated histone h3 were not large enough to conduct the correlative analysis.

Acetylated Histone H3 and Overall Response Association

Overall Study

Anti-Infective Agents

Thalidomide

Immunosuppressive Agents

Anti-Bacterial Agents

Angiogenesis Inhibitors

Growth Inhibitors

Athanasios Fassas, M.D.

The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.

Patients will receive thalidomide in the oral form each night before bed. The dose of thalidomide will be increased each week until week 7 as long as there are no significant side effects.

Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered, if any, and provide the available treatments for side effects accordingly. Blood tests will be done to monitor the tumor response.

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

Celgene Corporation

University of Arkansas

Infections

Syndrome

Hematologic Neoplasms

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Hodgkin Disease

Lymphoma, B-Cell

Burkitt Lymphoma

Leukemia, Hairy Cell

Lymphoma, Non-Hodgkin

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

B-cell Lymphoma

Marginal Zone Lymphoma

Hodgkin Lymphoma

Acute Graft Versus Host Disease

Hairy Cell Leukemia

Richter Syndrome

Chronic Graft Versus Host Disease

Pembrolizumab

Immune Checkpoint Inhibitors

A nonrandomized study that will be conducted in 2 stages. In the first stage, (Safety), subjects will receive Acalabrutinib Dose A orally administered (PO) twice daily (BID) in combination with Pembrolizumab Dose B administered every 3 weeks (Q3W).

The second stage was an expansion of Cohorts with the same dose regimen as the first stage. An additional expansion in subjects with Myelofibrosis was planned but not conducted.

AstraZeneca Clinical Study Information Center

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

This is a Phase 1b/2, open-label, nonrandomized study that will be conducted in 2 stages. In the first stage, Part 1 of the study will determine the safety and preliminary efficacy of acalabrutinib and pembrolizumab in a limited group of B-cell malignancies. In the second stage, Part 2 allows for possible expansion cohorts into a wider range of B-cell malignancies, and Part 3 will evaluate the combination in subjects with myelofibrosis (MF).

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.

Severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03

Number of participants with CTCAE Grade 5 (fatal) adverse events

Study drug-related AEs were those assessed by investigator as related to study treatment.

The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.

Grade 5 (fatal) AEs assessed by investigator as related to study treatment.

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher.

Grade 5 events were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.

Grade 5 AEs were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.

AEs that discontinuation of study treatment, or a reduction in dosage, or a delay (temporary withholding) in treatment.

An adverse event that resulted in the permanent discontinuation of study treatment in the study.

An adverse event that caused a temporary withholding of study treatment.

An adverse event that resulted in a reduction in the dosage of study treatment for that participant.

The percentage of subjects who achieve a partial response or complete response

The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause

The interval from the first dose date of acalabrutinib or pembrolizumab to the earlier of the first documentation of objective disease progression or death from any cause

The time from the first dose date of acalabrutinib or pembrolizumab until date of death due to any cause

The time from the first dose date of acalabrutinib or pembrolizumab to the start of the next treatment other than the study treatment

Merck Sharp & Dohme LLC

Acerta Pharma BV

All participants in this study received both study drugs and were analyzed together as a single treatment arm. There were 3 Stages to the study (representing different disease histologies) and not 3 arms in the study. Study data are presented by disease histology for all subjects in Stage 1 (N=30) and Stage 2 (N=131) as TOTAL subjects (N=161). Stage 3 of the study was not conducted.

All participants in this study received both study drugs and were therefore analysed together as a single treatment arm.

Participants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment.

The study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.

Acalabrutinib + Pembrolizumab

Hispanic or Latino

Not Hispanic or Latino

Not Reported

Race/Ethnicity, Customized

American Indian or Alaska Native

Asian

Black or African American

All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the safety of the combination study treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders	NCT01177527	Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L...		18 Years -	Dana-Farber Cancer Institute
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia	NCT04624906	Waldenstrom Mac...	Acalabrutinib Bendamustine Rituximab	18 Years -	Sunnybrook Health Sciences Centre
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia	NCT00936611	Waldenstrom's M...	LBH589	18 Years -	Dana-Farber Cancer Institute
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia	NCT00936611	Waldenstrom's M...	LBH589	18 Years -	Dana-Farber Cancer Institute
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia	NCT00083707	Waldenstrom Mac...	Thalidomide	18 Years -	University of Arkansas
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia	NCT04624906	Waldenstrom Mac...	Acalabrutinib Bendamustine Rituximab	18 Years -	Sunnybrook Health Sciences Centre
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	NCT02362035	Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk...	Acalabrutinib Pembrolizumab	18 Years -	Acerta Pharma BV
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders	NCT01177527	Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L...		18 Years -	Dana-Farber Cancer Institute
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	NCT02362035	Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk...	Acalabrutinib Pembrolizumab	18 Years -	Acerta Pharma BV

Spots Global Cancer Trial Database for waldenstrom

Every month we try and update this database with for waldenstrom cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for waldenstrom

Every month we try and update this database with for waldenstrom cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for waldenstrom cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.